Orphalan
Industry · 6 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients Wilson's Disease | Phase 3 | 2026-05-01 |
| Completed | Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride Wilson's Disease | Phase 2 | 2025-07-15 |
| Completed | Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily). Wilson's Disease | Phase 1 | 2024-01-16 |
| Completed | Real World Evidence Study in Subjects With Wilson's Disease Wilson Disease | — | 2023-06-28 |
| Recruiting | International Wilson's Disease Patient Registry (iWilson Registry) Wilson's Disease | — | 2022-06-29 |
| Completed | Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease Wilson Disease | Phase 3 | 2018-09-03 |